Publication Date:
2013-05-25
Description:
Cramer et al. (Reports, 23 March 2012, p. 1503; published online 9 February 2012) demonstrates short-term bexarotene treatment clearing preexisting beta-amyloid deposits from the brains of APP/PS1DeltaE9 mice with low amyloid burden, providing a rationale for repurposing this anticancer agent as an Alzheimer's disease (AD) therapeutic. Using a nearly identical treatment regimen, we were unable to detect any evidence of drug efficacy despite demonstration of target engagement.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Price, Ashleigh R -- Xu, Guilian -- Siemienski, Zoe B -- Smithson, Lisa A -- Borchelt, David R -- Golde, Todd E -- Felsenstein, Kevin M -- New York, N.Y. -- Science. 2013 May 24;340(6135):924-d. doi: 10.1126/science.1234089.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉Center for Translational Research in Neurodegenerative Disease, Department of Neuroscience, McKnight Brain Institute, University of Florida College of Medicine, 1275 Center Drive, Gainesville, FL 32610, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/23704553" target="_blank"〉PubMed〈/a〉
Keywords:
Alzheimer Disease/*drug therapy/*metabolism
;
Amyloid beta-Peptides/*metabolism
;
Animals
;
Apolipoproteins E/*metabolism
;
Brain/*metabolism
;
Male
;
Tetrahydronaphthalenes/*pharmacology/*therapeutic use
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
